Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
04:47pm, Wednesday, 17'th Jul 2024
VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delt
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
10:01am, Thursday, 04'th Jul 2024
One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regard
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and gr
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
02:31pm, Thursday, 06'th Jun 2024
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #hepatitisd--New data from Vir Biotechnology reinforces the potential for a transformative treatment for hepatitis delta, the most severe form of viral hepatiti
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Wednesday, 29'th May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
08:05am, Wednesday, 29'th May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
04:05pm, Thursday, 23'rd May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT.
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
08:05am, Wednesday, 22'nd May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B prog
Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'
08:00am, Wednesday, 22'nd May 2024
BEAVERTON, Ore.--(BUSINESS WIRE)-- #familyfestivals--Reser's Fine Foods kicks off 2024 ‘Good Times Tour' with free delicious samples and fun activities in their booth at festivals throughout 2024.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker post
DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient h
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
11:01am, Tuesday, 07'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable,
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
12:35am, Friday, 03'rd May 2024
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Maria
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
07:06pm, Thursday, 02'nd May 2024
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.
